PBF-677 + mesalazine

PBF-677 + mesalazine is a combination therapy that has been investigated for the treatment of ulcerative colitis. This combination consists of PBF-677, an investigational drug developed by Palobiofarma, and mesalazine (also known as 5-aminosalicylic acid or 5-ASA), which is a standard first-line therapy for mild-to-moderate ulcerative colitis. ## Clinical Development The combination has been studied in a Phase IIa clinical trial that evaluated its safety, tolerability, and preliminary efficacy in patients with mild to moderate ulcerative colitis in flair condition. The trial recruited 32 patients, with 22 receiving PBF-677 (200mg) + mesalazine (4g) and 10 receiving only mesalazine (4g) once daily for 28 days[1]. ## Efficacy Results The clinical trial demonstrated that PBF-677 + mesalazine treatment achieved statistical significance in all efficacy parameters measured. Specifically, the combination therapy showed: - Statistically significant improvement of rectal bleeding and stool frequency compared with mesalazine alone[1][2] - Statistically significant improvement in the Partial Mayo Score compared with mesalazine alone[2] - Significant reduction of C-reactive protein (CRP) levels on day 28 and at the end of the study compared to baseline levels[2] - Significant reduction of fecal calprotectin levels from day 14 onwards compared with baseline levels[2] ## Safety Profile The drug combination was reported to be safe and well tolerated when administered with the standard of care treatment mesalazine[1]. This is an important finding as safety is a critical consideration for new treatments for inflammatory bowel diseases. ## Development Status The Phase IIa trial was completed in 2021, with Palobiofarma announcing positive results in November 2021[1]. According to the available information, Palobiofarma is currently evaluating different partnering/licensing opportunities for this asset[1]. The combination therapy represents a potential new treatment option for patients with ulcerative colitis, particularly those who may not respond adequately to mesalazine alone. The statistically significant improvements observed across multiple efficacy parameters suggest that PBF-677 may enhance the therapeutic effects of standard mesalazine treatment in this patient population.

Other names

5-aminosalicylic acid5-ASA